Sanofi wins in late-stage trial for blood disorder candidate (NASDAQ:SNY)
Panama7 Sanofi (NASDAQ:SNY) announced Tuesday that rilzabrutinib, an oral therapy for an autoimmune blood disorder called immune thrombocytopenia (ITP), reached the primary endpoint in a Phase 3 trial. The study, named LUNA 3, enrolled…
